Drug Trial Radar · NCT05582499
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Last checked: Nov 19, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
716
Planned (sponsor's estimate)
Start
Nov 1, 2022
Primary completion
Dec 31, 2027
Study completion Sep 2029
Sponsor
- Lead sponsor
- Fudan UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 17, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to establish a prospective, single-center platform research based on clinical subtypes to explore precision neoadjuvant therapy in patients with operable breast cancer who met the indications for neoadjuvant chemotherapy and by the update of basic translational research in the center, especially the refinement of typing, the discovery of new targets and the development of novel targeted drugs, verified the effectiveness of new targeted drugs in neoadjuvant therapy.
Conditions
- Breast Neoplasm
- Breast Cancer
- Breast Tumors
- Triple-Negative Breast Cancer (TNBC)
- HER2-positive Breast Cancer
- HER2-negative Breast Cancer
- Hormone Receptor Positive Tumor
- Hormone Receptor Negative Tumor
- Early-stage Breast Cancer
- Locally Advanced Breast Cancer
Interventions
DalpiciclibDrug
an oral cyclin-dependent kinases (CDK) 4/6 inhibitor
PyrotinibDrug
an irreversible dual pan-erbb receptor tyrosine kinase receptor tyrosine kinase (ERBB) inhibitor
SHR-A1811Drug
an anti-HER2 antibody-drug conjugate (ADC)
SHR-1316Drug
an anti-programmed death ligand 1 (PD-L1) antibody
CamrelizumabDrug
an anti-programmed death-1 (PD1) antibody
SHR-A1921Drug
Trophoblast cell-surface antigen 2 (TROP2) ADC
PertuzumabDrug
Pertuzumab
TrastuzumabDrug
Trastuzumab
GoserelinDrug
goserelin
LetrozoleDrug
letrozole
Nab paclitaxelDrug
Albumin paclitaxel
CarboplatinDrug
Carboplatin
EpirubicinDrug
Epirubicin
CyclophosphamideDrug
Cyclophosphamide
FluzoparibDrug
an original poly adenosine diphosphate-ribose polymerase (PARP) inhibitor
ApatinibDrug
tyrosine kinase inhibitors
FamitinibDrug
tyrosine kinase inhibitors
HB1801Drug
Albumin docetaxel
LEMDrug
liposome-entrapped mitoxantrone
TQB2102Drug
an anti-HER2 ADC
BenmelstobartDrug
an anti-PDL1 antibody
AnlotinibDrug
an tyrosine kinase inhibitor
TQB2868Drug
anti-PD-1/TGF-βRII
IvonescimabDrug
an anti-PD-1/VEGF bispecific antibody
JS207Drug
an anti-PD-1/VEGF bispecific antibody
JSKN003Drug
an anti-HER2 ADC
HRS-4508Drug
an HER2 inhibitor
SHR-4602Drug
an anti-HER2 ADC
paclitaxelDrug
paclitaxel
HRS-6209Drug
an oral cyclin-dependent kinases 4 (CDK4) inhibitor
9MW2821Drug
a Nectin-4 antibody-drug conjugate (ADC)
IBI354Drug
an anti-HER2 ADC
Stereotactic Body Radiation Therapy (SBRT)Radiation
Stereotactic Body Radiation Therapy (SBRT) is performed within 5 calendar days prior to the initiation of drug therapy. SBRT is delivered to the primary tumor in 3 fractions of 8 Gy each (total 24 Gy) over 3-5 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pathological complete response rate (pCR)Time frame: through study completion, up to 24 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center Shanghai, China, 200032
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.